Last $9.89 USD
Change Today +0.18 / 1.85%
Volume 755.1K
HALO On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 08/26/14 All times are local (Market data is delayed by at least 15 minutes).

Financial Statements for halozyme therapeutics inc (HALO)

Year over year, Halozyme Therapeutics, Inc. has seen their bottom line shrink from a loss of $53.6M USD to an even larger loss of $83.5M USD despite an increase in revenues from $42.3M USD to $54.8M USD. An increase in the percentage of sales devoted to cost of goods sold from 168.08% to 187.75% was a key component in the falling bottom line in the face of rising revenues.
Currency in
Millions of US Dollars
As of:Dec 31
2010
Reclassified
Dec 31
2011
Restated
Dec 31
2012
Restated
Dec 31
2013
4 Year
Trend
Revenues13.656.142.354.8
TOTAL REVENUES13.656.142.354.8
Cost of Goods Sold51.657.871.1102.9
GROSS PROFIT-37.9-1.7-28.8-48.1
Selling General & Admin Expenses, Total15.018.124.832.3
OTHER OPERATING EXPENSES, TOTAL15.018.124.832.3
OPERATING INCOME-53.0-19.8-53.6-80.4
Interest Expense-------3.3
Interest and Investment Income0.00.10.11.3
NET INTEREST EXPENSE0.00.10.1-1.9
Other Non-Operating Income (Expenses)0.0------
EBT, EXCLUDING UNUSUAL ITEMS-52.9-19.8-53.6-82.4
Merger & Restructuring Charges-1.3------
Gain (Loss) on Sale of Investments-------1.1
Other Unusual Items, Total1.0------
Other Unusual Items1.0------
EBT, INCLUDING UNUSUAL ITEMS-53.2-19.8-53.6-83.5
Earnings from Continuing Operations-53.2-19.8-53.6-83.5
NET INCOME-53.2-19.8-53.6-83.5
NET INCOME TO COMMON INCLUDING EXTRA ITEMS-53.2-19.8-53.6-83.5
NET INCOME TO COMMON EXCLUDING EXTRA ITEMS-53.2-19.8-53.6-83.5
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HALO:US $9.89 USD +0.18

HALO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amphastar Pharmaceuticals Inc $11.50 USD +0.04
View Industry Companies
 

Industry Analysis

HALO

Industry Average

Valuation HALO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 20.4x
Price/Book 21.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 17.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HALOZYME THERAPEUTICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.